The role of progesterone and GABA in PMS/PMDD

The Premenstrual Syndromes: PMS and PMDD

Volumn , Issue , 2007, Pages 117-120

  Bäckström, Torbjörn ^a   Andréen, Lotta ^a   Björn, Inger ^a   Johansson, Inga Maj ^a   Löfgren, Magnus ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85010446499     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (46)

1. Bäckström T, Sanders D, Leask RM et al. Mood, sexuality, hormones and the menstrual cycle. II. Hormone levels and their relationship to premenstrual syndrome. Psychosom Med 1983; 45:503-7.
2. Hamarbäck S, Bäckström T. Induced anovulation as treatment of premenstrual tension syndrome. A double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet Gynecol Scand 1988; 67:159-66.
3. Hammarbäck S, Ekholm UB, Bäckström T. Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome. Acta Endocrinol 1991; 125:132-7.
4. Mortola JF. Applications of gonadotropin-releasing hormone analogues in the treatment of premenstrual syndrome. Clin Obstet Gynecol 1993; 36:753-63.
5. Andréen L, Sundström-Poromaa I, Bixo M et al. Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone. Psychoneuroendocrinology 2005; 30:212-24.
6. Björn I, Bixo M, Strandberg-Nöjd K et al. Negative mood changes during hormone replacement therapy: a comparison between two progestogens. Am J Obstet Gynecol 2000; 183:1419-26.
7. Hammarbäck S, Bäckström T, Holst J et al. Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen-progestagen postmenopausal replacement treatment. Acta Obstet Gynecol Scand 1985; 64:393-7.
8. Chan AF, Mortola JF, Wood SH, Yen SS. Persistence of premenstrual syndrome during low-dose administration of the progesterone antagonist RU 486. Obstet Gynecol 1994; 84(6):1001-5.
9. Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 1986; 232(4753):1004-7.
10. Bäckström T, Andersson A, Andree L et al. Pathogenesis in menstrual cycle-linked CNS disorders. Ann NY Acad Sci 2003; 1007:42-53.
11. Sieghart W. Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes. Pharmacol Rev 1995; 47(2):181-234.
12. Carl P, Hogskilde S, Nielsen JW et al. Pregnanolone emulsion. A preliminary pharmacokinetic and pharmacodynamic study of a new intravenous anaesthetic agent. Anaesthesia 1990; 45(3):189-97.
13. Timby E, Balgard M, Nyberg S et al. Pharmacokinetic and behavioral effects of allopregnanolone in healthy women. Psychopharmacology (Berl) 2006; 186(3):414-24.
14. Landgren S, Aasly J, Backstrom T, Dubrovsky B, Danielsson E. The effect of progesterone and its metabolites on the interictal epileptiform discharge in the cat’s cerebral cortex. Acta Physiol Scand 1987; 131(1):33-42.
15. Wieland S, Lan NC, Mirasedeghi S, Gee KW. Anxiolytic activity of the progesterone metabolite 5 alpha-pregnan-3 alpha-ol-20-one. Brain Res 1991; 565:263-8.
16. Miczek KA, Fish EW, De Bold JF. Neurosteroids, GABAA receptors, and escalated aggressive behavior. Horm Behav 2003; 44:242-57.
17. Johansson IM, Birzniece V, Lindblad C, Olsson T, Backotsom T. Allopregnanolone inhibits learning in the Morris water maze. Brain Res 2002; 934:125-31.
18. Gulinello M, Gong QH, Li X et al. Short-term exposure to a neuroactive steroid increases alpha4 GABA(A) receptor subunit levels in association with increased anxiety in the female rat. Brain Res 2001; 910:55-66.
19. Beauchamp MH, Ormerod BK, Jhamandas K, Boegman RJ, Beninger RJ. Neurosteroids and reward: allopregnanolone produces a conditioned place aversion in rats. Pharmacol Biochem Behav 2000; 67:29-35.
20. Masia SL, Perrine K, Westbrook L, Alpor K, Devensky O. Emotional outbursts and post-traumatic stress disorder during intracarotid amobarbital procedure. Neurology 2000; 54(8):1691-3.
21. Sveindottir H, Backstrom T. Prevalence of menstrual cycle symptom cyclicity and premenstrual dysphoric disorder in a random sample of women using and not using oral contraceptives. Acta Obstet Gynecol Scand 2000; 79(5):405-13.
22. Weinbroum AA, Szold O, Ogorek D, Flaishon R. The midazolaminduced paradox phenomenon is reversible by flumazenil. Epidemiology, patient characteristics and review of the literature. Eur J Anaesthesiol 2001; 18(12):789-97.
23. Paul SM, Purdy RH. Neuroactive steriods. FASEB J 1992; 6:2311-22.
24. Wang M, Bäckström T, Sundström I et al. Neuroactive steroids and central nervous system disorders. Int Rev Neurobiol 2001; 46:421-59.
25. Ben-Porath DD, Taylor SP. The effects of diazepam (valium) and aggressive disposition on human aggression: an experimental investigation. Addict Behav 2002; 27:167-77.
26. Wenzel RR, Bartel T, Eggebrecht H, Philipp T, Erbel R. Centralnervous side effects of midazolam during transesophageal echocardiography. J Am Soc Echocardiogr 2002; 15:1297-1300.
27. Kurthen M, Linke DB, Reuter BM, Hufnagel A, Elger CE. Severe negative emotional reactions in intracarotid sodium amytal procedures:further evidence for hemispheric asymmetries? Cortex 1991; 27:333-7.
28. Dougherty DM, Cherek DR, Bennett RH. The effects of alcohol on the aggressive responding of women. J Stud Alcohol 1996; 57:178-86.
29. Andreen L, Bixo M, Nyberg S, Sundström-Poromaa I, Bäckström T. Progesterone effects during sequential hormone replacement therapy. Eur J Endocrinol 2003; 148:571-7.
30. Björn I, Bixo M, Nöjd K et al. The impact of different doses of medroxyprogesterone acetate on mood symptoms in sequential hormonal therapy. Gynecol Endocrinol 2002; 16:1-8.
31. Andréen L, Sundström-Poromaa I, Bixo M, Nyberg S, Bäckström T. Allopregnanolone concentration and mood - a bimodal association in postmenopausal women treated with oral progesterone. Psychopharmacology 2006; 187(2):209-21.
32. Luisi S, Petraglia F, Benedetto C et al. Serum allopregnanolone levels in pregnant women: changes during pregnancy, at delivery, and in hypertensive patients. J Clin Endocrinol Metab 2000; 85:2429-33.
33. Wang M, Seippel L, Purdy RH, Bäckström T. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5 alpha-pregnane-3,20-dione and 3 alphahydroxy-5 alpha-pregnan-20-one. J Clin Endocrinol Metab 1996; 81:1076-82.
34. Gourley SL, Debold JF, Yin W, Cook J, Miczek KA. Benzodiazepines and heightened aggressive behavior in rats:reduction by GABA(A)/alpha(1) receptor antagonists. Psychopharmacology (Berl) 2005; 178(2-3):232-40.
35. Bjorn I, Sundstrom-Poromaa I, Bixo M et al. Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy. J Clin Endocrinol Metab 2003; 88(5):2026-30.
36. Schmidt PJ, Nieman LK, Danaceau MA et al. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 1998; 338:209-16.
37. Hammarbäck S, Damber JE, Bäckström T. Relationship between symptom severity and hormone changes in women with premenstrual syndrome. J Clin Endocrinol Metab 1989; 68:125-30.
38. Dhar V, Murphy BE. Double-blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology 1990; 15:489-93.
39. Cullberg J. Mood changes and menstrual symptoms with different gestagen/estrogen combinations. A double blind comparison with placebo. Acta Psychiat Scand 1972; 236 (Suppl):1-84.
40. Sundström I, Andersson A, Nyberg S et al. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology 1998; 67:126-38.
41. Sundström I, Ashbrook D, Bäckström T. Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Psychoneuroendocrinology 1997; 22:25-38.
42. Nyberg S, Wahlström G, Bäckström T, Sundström-Poromaa I. Altered sensitivity to alcohol in the late luteal phase among patients with premenstrual dysphoric disorder. Psychoneuroendocrinology 2004; 29:767-77.
43. Löfgren M, Johansson IM, Meyerson B, Lundgren P, Bäckström T. Progesterone withdrawal effects in the open field test can be predicted by elevated plus maze performance. Horm Behav 2006; 50(2):208-15.
44. Zhu D, Birzniece V, Bäckström T, Wahlström G. Dynamic aspects of acute tolerance to allopregnanolone evaluated using anaesthesia threshold in male rats. Br J Anaesth 2004; 93:560-7.
45. Birzniece V, Türkmen S, Lindblad C et al. GABA-A receptor mRNA changes in acute allopregnanolone tolerance. Eur J Pharmacol 2006; 535(1-3):125-34.
46. Sundström I, Nyberg S, Bäckström T. Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. Neuropsychopharmacology 1997; 17:370-81.